Canada based Canopy Growth has declared its intent to enter the UK market, by unveiling new pharmaceutical company Spectrum Biomedical UK – a joint venture between Canopy Growth and Beckley Canopy.
Claiming “significant real world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products”, the new joint company plans to be the exclusive distributor of Spectrum Cannabis medicinal products in the UK market.
The new partnership formed to address a groundswell of patient need for high quality, standardised cannabis-based medicinal products in the UK, after the UK government made it legal for specialist doctors to prescribe medical marijuana for patients with severe clinical need in November 2018.
“There is significant real world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products. However, due to the current regulations and lack of education about medicinal cannabis among clinicians in the UK, there remain considerable obstacles to patient access,” said Dr Mark Ware, chief medical officer at Canopy Growth.
“Spectrum UK has the expertise and ambition to simplify the UK medicinal cannabis landscape and ensure access to cannabis-based medicinal products for patients with great clinical unmet need.”
